BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. The company is partnered with Auxilium Pharmaceuticals, Inc. for injectable collagenase (XIAFLEX®). XIAFLEX is approved in the U.S. for the treatment of Dupuytren’s contracture in adults with a palpable cord in the palm. Auxilium is also developing XIAFLEX for the treatment of Peyronie's disease, which is currently in Phase 3 pivotal clinical trials, as well as for Frozen Shoulder (Adhesive Capsulitis) and cellulite.
Pfizer, Inc. is responsible for marketing XIAPEX® (trademarked XIAPEX in Europe) for Dupuytren’s contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie’s disease in these same territories.
Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren’s contracture and Peyronie’s disease in Japan. BioSpecifics is developing XIAFLEX internally for human and canine lipomas.
